AKA-358
Pentosan polysulfate sodium

Cat. No.

AKA-358

CAS No.

140207-93-8

MF

(C5H10O14S2NA2) N

MW

4000-6000

Pentosan polysulfate sodium is a bioavailable semi-synthetic molecule with anti-inflammatory, chondrogenic, and anti-HIV activities for interstitial cystitis research.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service
Need help? Our team of experienced experts is here for you with full support.
86-28-85159085
info@aktin.com
Inquiry
Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Pentosan polysulfate sodium
CAS No.
140207-93-8
MF
(C5H10O14S2NA2) N
MW
4000-6000
Specification
90%-110%
Research Area
anticoagulant, fibrinolytic, anti-inflammatory, cartilage-protective, antiviral
Description
Pentosan polysulfate sodium is a bioavailable semi-synthetic molecule with anti-inflammatory, chondrogenic, and anti-HIV activities for interstitial cystitis research.
Packing:  500g/bag, 1kg/bag, 5kg/bag
Availability:  In stock
API Current Development Status: A3---Process Development / Scale-Up
Reference: 
Aktin major API development processes:
A1.Feasibility / Route Development
A2.Laboratory Process Development
A3.Process Development / Scale-Up
A4.GMP Clinical Development
A5.Commercial GMP Supply
Documents
  • Specification sheet
For Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS) etc., please enquiry by email: info@aktin.com
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Schuchman EH, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One. 2013;8(1):e54459. [2]. Baba M, et al. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res. 1988 Sep;9(6):335-43. [3]. Wu J, et al. Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice. Lab Invest. 2011 Oct;91(10):1459-71.
Disclaimer
The information provided on generic APIs is for general reference and market assessment purposes only. Regulatory status, market availability, specifications, patents, and commercial terms may vary by country and change over time. Users should independently verify all information with the relevant regulatory authorities and qualified professionals before making any regulatory, manufacturing, investment, or commercial decisions.
We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-373
Abietic acid

CAS No.:514-10-3

MF:C20H30O2

View Details
AKA-372
Dipexion™ Fmoc-Val-Ser(psi(Me,Me)pro)-OH

CAS No.:186023-49-4

MF:C26H30N2O6

View Details
AKA-371
Dipexion™ Fmoc-Gly-Ser(psi(Me,Me)pro)-OH

CAS No.:1095952-22-9

MF:C23H24N2O6

View Details
AKA-370
Oxymatrine

CAS No.:16837-52-8

MF:C15H24N2O2

View Details
AKA-369
Matrine

CAS No.:519-02-8

MF:C15H24N2O

View Details
AKA-368
Dipexion™ Fmoc-Lys(Boc)-Thr[PSI(Me,Me)Pro]-OH

CAS No.:911838-56-7

MF:C33H43N3O8

View Details
AKA-367
Dipexion™ Fmoc-Leu-Ser[PSI(Me,Me)Pro]-OH

CAS No.:339531-50-9

MF:C27H32N2O6

View Details
AKA-366
Dipexion™ Fmoc-Ser(tBu)-Thr[PSI(Me,Me)Pro]-OH

CAS No.:1266350-99-5

MF:C29H36N2O7

View Details
AKA-365
Dipexion™ Fmoc-Glu(OtBu)-Thr[PSI(Me,Me)Pro]-OH

CAS No.:957780-56-2

MF:C31H38N2O8

View Details
AKA-364
Dipexion™ Fmoc-Lys(Boc)-Ser[PSI(Me,Me)Pro]-OH

CAS No.:957780-54-0

MF:C32H41N3O8

View Details
* Some statements have not been evaluated by national authorities.
* Some products are not intended to diagnose, treat, cure, or prevent any disease.
* For literature supporting, please contact us directly.
Cart
TotalProducts
Request Quote
  • China
  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Central African Republic
  • Chad
  • Chile
  • Colombia
  • Comoros
  • Congo (Brazzaville)
  • Congo (Kinshasa)
  • Cook Islands
  • Costa Rica
  • Côte d'Ivoire
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • East Timor (Timor-Leste)
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Eswatini
  • Ethiopia
  • Fiji
  • Finland
  • France
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Greece
  • Grenada
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • South Korea
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Mozambique
  • Myanmar (Burma)
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • North Macedonia
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Rwanda
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • Spain
  • Sri Lanka
  • Sudan
  • South Sudan
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Tajikistan
  • Tanzania
  • Thailand
  • Togo
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates (UAE)
  • United Kingdom (UK)
  • United States (US)
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Vatican City
  • Venezuela
  • Vietnam
  • Yemen
  • Zambia
  • Zimbabwe
  • Beijing-Beijing
  • Tianjin-Tianjin
  • Hebei-Shijiazhuang
  • Shanxi-Taiyuan
  • Inner Mongolia-Hohhot
  • Liaoning-Shenyang
  • Jilin-Changchun
  • Heilongjiang-Harbin
  • Shanghai-Shanghai
  • Jiangsu-Nanjing
  • Zhejiang-Hangzhou
  • Anhui-Hefei
  • Fujian-Fuzhou
  • Jiangxi-Nanchang
  • Shandong-Jinan
  • Henan-Zhengzhou
  • Hubei-Wuhan
  • Hunan-Changsha
  • Guangdong-Guangzhou
  • Guangxi-Nanning
  • Hainan-Haikou
  • Chongqing-Chongqing
  • Sichuan-Chengdu
  • Guizhou-Guiyang
  • Yunnan-Kunming
  • Tibet-Lhasa
  • Shaanxi-Xi'an
  • Gansu-Lanzhou
  • Qinghai-Xining
  • Ningxia-Yinchuan
  • Xinjiang-Urumqi
  • Hong Kong-Hong Kong
  • Macao-Macao
  • Taiwan-Taipei